Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies. (2023)
Attributed to:
Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/cam4.5799
PubMed Identifier: 37021939
Publication URI: http://europepmc.org/abstract/MED/37021939
Type: Journal Article/Review
Volume: 12
Parent Publication: Cancer medicine
Issue: 9
ISSN: 2045-7634